Asset Details
Do you wish to reserve the book?
Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting
Do you wish to request the book?
Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting
2017
Overview
Context and objectives
The impact of complementary and integrative medicine (CIM) on adherence to chemotherapy regimens is unclear. We explored the effect of patient-tailored CIM treatments on the relative dose intensity (RDI) of chemotherapy among patients with breast and gynecological cancer.
Methods
Chemotherapy-treated patients with breast or gynecological cancer were referred by their oncology healthcare professional to a CIM treatment program. Adherence to integrative care (AIC) was defined as ≥4 CIM treatments, with ≤30 days between each treatment. Relative dose intensity (RDI) of chemotherapy was compared between CIM-treated patients and controls, and among adherence sub-groups.
Results
RDI was calculated for 106-treated patients (62 AIC) and 75 controls. Baseline-to-6-week RDI values were similar in both study arms, with a lower % RDI <1.0 among controls at 12 weeks (47 vs. 57.5%;
P
= 0.036). Adherence sub-groups had similar RDI values, though at 6 weeks, the AIC group had lower % RDI <1.0 (33.9 vs. 54.5%,
P
= 0.046). Total administered medication dose/planned dose was higher in the AIC group at 6 weeks for paclitaxel (82%/50%,
P
= 0.025) and carboplatin (87%/67%,
P
= 0.028), with no difference in cytoxan/adriamycin dosages.
Conclusion
A patient-tailored CIM program for patients with breast or gynecological cancer may be associated with a lower percentage of reduced RDI at 6 weeks, this in a sub-group of patients with higher adherence to CIM, and for specific chemotherapy agents, though this benefit did not persist after 12 weeks. Further research is needed to better understand the impact of CIM in cancer care.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
Antineoplastic Agents - administration & dosage
/ Breast
/ Breast Neoplasms - drug therapy
/ Cancer
/ Complementary Therapies - methods
/ Dosage
/ Female
/ Genital Neoplasms, Female - drug therapy
/ Genital Neoplasms, Female - therapy
/ Humans
/ Medicine
/ Oncology
/ Original Article – Clinical Oncology
/ Original – Clinical Oncology
/ Patients
